JP2018513149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513149A5 JP2018513149A5 JP2017552973A JP2017552973A JP2018513149A5 JP 2018513149 A5 JP2018513149 A5 JP 2018513149A5 JP 2017552973 A JP2017552973 A JP 2017552973A JP 2017552973 A JP2017552973 A JP 2017552973A JP 2018513149 A5 JP2018513149 A5 JP 2018513149A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable domain
- chain variable
- amino acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021086783A JP7273101B2 (ja) | 2015-04-08 | 2021-05-24 | Ｃｄ３８に結合する抗体治療剤 |
| JP2022101169A JP2022118222A (ja) | 2015-04-08 | 2022-06-23 | Ｃｄ３８に結合する抗体治療剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144901P | 2015-04-08 | 2015-04-08 | |
| US62/144,901 | 2015-04-08 | ||
| PCT/US2016/026567 WO2016164669A2 (en) | 2015-04-08 | 2016-04-08 | Antibody therapeutics that bind cd38 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086783A Division JP7273101B2 (ja) | 2015-04-08 | 2021-05-24 | Ｃｄ３８に結合する抗体治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513149A JP2018513149A (ja) | 2018-05-24 |
| JP2018513149A5 true JP2018513149A5 (https=) | 2019-05-16 |
| JP7068825B2 JP7068825B2 (ja) | 2022-05-17 |
Family
ID=57072959
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552973A Expired - Fee Related JP7068825B2 (ja) | 2015-04-08 | 2016-04-08 | Ｃｄ３８に結合する抗体治療剤 |
| JP2021086783A Active JP7273101B2 (ja) | 2015-04-08 | 2021-05-24 | Ｃｄ３８に結合する抗体治療剤 |
| JP2022101169A Pending JP2022118222A (ja) | 2015-04-08 | 2022-06-23 | Ｃｄ３８に結合する抗体治療剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086783A Active JP7273101B2 (ja) | 2015-04-08 | 2021-05-24 | Ｃｄ３８に結合する抗体治療剤 |
| JP2022101169A Pending JP2022118222A (ja) | 2015-04-08 | 2022-06-23 | Ｃｄ３８に結合する抗体治療剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10059774B2 (https=) |
| EP (2) | EP4180058A1 (https=) |
| JP (3) | JP7068825B2 (https=) |
| CN (2) | CN113527495A (https=) |
| AR (1) | AR104213A1 (https=) |
| ES (1) | ES2927119T3 (https=) |
| TW (1) | TW201702264A (https=) |
| WO (2) | WO2016164669A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10100118B2 (en) | 2015-04-08 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD123 |
| ES2927119T3 (es) | 2015-04-08 | 2022-11-02 | Sorrento Therapeutics Inc | Productos terapéuticos de anticuerpos que se unen a CD38 |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| CN118772278A (zh) | 2017-06-02 | 2024-10-15 | 辉瑞公司 | Flt3的特异性抗体及其用途 |
| WO2018224682A1 (en) | 2017-06-08 | 2018-12-13 | Tusk Therapeutics Ltd | Cd38 modulating antibody |
| KR102719065B1 (ko) | 2017-06-08 | 2024-10-17 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| KR102771835B1 (ko) | 2017-06-20 | 2025-02-26 | 비바솔, 인코포레이티드. | Cd38 항체 약물 접합체 |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| SG11202000321PA (en) | 2017-08-16 | 2020-02-27 | Black Belt Therapeutics Ltd | Cd38 modulating antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| AU2018316522B2 (en) * | 2017-08-16 | 2025-02-20 | Black Belt Therapeutics Limited | CD38 antibody |
| CA3080109A1 (en) * | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| SG11202008568WA (en) * | 2018-03-09 | 2020-10-29 | Sorrento Therapeutics Inc | Dimeric antigen receptors (dar) |
| CN112313250B (zh) * | 2018-06-20 | 2024-10-01 | 索伦托药业有限公司 | 结合cd38的变体抗体 |
| CA3111651A1 (en) | 2018-09-11 | 2020-03-19 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use |
| JP7555953B2 (ja) * | 2019-03-29 | 2024-09-25 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ３８に結合する操作されたバリアント抗体 |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| AU2020299774A1 (en) * | 2019-07-03 | 2022-01-20 | Peptidream Inc. | CD38-binding agents and uses thereof |
| TW202124437A (zh) * | 2019-08-19 | 2021-07-01 | 美商潘迪恩營運公司 | 以ｐｄ－１促效劑進行之標靶免疫耐受性 |
| WO2021113596A2 (en) | 2019-12-05 | 2021-06-10 | Sorrento Therapeutics, Inc. | Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| EP4107189A4 (en) * | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS |
| WO2022015956A1 (en) | 2020-07-15 | 2022-01-20 | Sorrento Therapeutics, Inc. | Improved process for dna integration using rna-guided endonucleases |
| BR112023003087A2 (pt) * | 2020-08-19 | 2023-03-28 | Pandion Operations Inc | Anticorpos anti-pd-1 multiparatópicos e usos dos mesmos |
| US12181485B2 (en) * | 2020-09-10 | 2024-12-31 | CASI Pharmaceuticals, Inc | Methods of blood screening |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| ATE240394T1 (de) | 1992-10-23 | 2003-05-15 | Immunex Corp | Methoden zur herstellung löslicher, oligomerer proteine |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US6938003B2 (en) | 2000-06-30 | 2005-08-30 | Mahesh Harpale | Method and apparatus for a credibility reporting system to augment an online exchange |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| AU2002329540A1 (en) * | 2001-06-20 | 2003-01-02 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| DK2511297T3 (en) | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies and their applications |
| CN1976950B (zh) * | 2004-02-06 | 2012-08-29 | 莫佛塞斯公司 | 抗cd38人抗体及其用途 |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| EP2860192B1 (en) * | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| WO2010141249A2 (en) * | 2009-06-02 | 2010-12-09 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-notch3 antibodies |
| DK2580243T3 (da) * | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| SI2621531T1 (sl) * | 2010-09-27 | 2017-06-30 | Morphosys Ag | Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US9120858B2 (en) * | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
| CA2919513A1 (en) * | 2013-07-15 | 2015-01-22 | Matthew J. Goldstein | Medical uses of cd38 agonists |
| ES2927119T3 (es) | 2015-04-08 | 2022-11-02 | Sorrento Therapeutics Inc | Productos terapéuticos de anticuerpos que se unen a CD38 |
-
2016
- 2016-04-08 ES ES16777327T patent/ES2927119T3/es active Active
- 2016-04-08 JP JP2017552973A patent/JP7068825B2/ja not_active Expired - Fee Related
- 2016-04-08 AR ARP160100954A patent/AR104213A1/es unknown
- 2016-04-08 CN CN202110836777.1A patent/CN113527495A/zh active Pending
- 2016-04-08 EP EP22190744.7A patent/EP4180058A1/en not_active Withdrawn
- 2016-04-08 WO PCT/US2016/026567 patent/WO2016164669A2/en not_active Ceased
- 2016-04-08 EP EP16777327.4A patent/EP3280443B1/en active Active
- 2016-04-08 US US15/094,384 patent/US10059774B2/en active Active
- 2016-04-08 CN CN201680033770.3A patent/CN107921122B/zh not_active Expired - Fee Related
- 2016-04-08 WO PCT/US2016/026545 patent/WO2016164656A1/en not_active Ceased
- 2016-04-08 TW TW105111134A patent/TW201702264A/zh unknown
- 2016-04-08 US US15/093,773 patent/US9951144B2/en active Active
-
2018
- 2018-08-04 US US16/055,065 patent/US10800852B2/en active Active
-
2020
- 2020-09-09 US US17/016,104 patent/US11999792B2/en active Active
-
2021
- 2021-05-24 JP JP2021086783A patent/JP7273101B2/ja active Active
-
2022
- 2022-06-23 JP JP2022101169A patent/JP2022118222A/ja active Pending